Literature DB >> 15010882

Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.

Sabine Merkelbach-Bruse1, Volkmar Hans, Micaela Mathiak, Rosario Sanguedolce, Riccardo Alessandro, Josef Rüschoff, Reinhard Büttner, Farzad Houshdaran, Lucia Gullotti.   

Abstract

Microsatellite instability (MSI) is a characteristic feature of up to 15% of colorectal cancers (CRC) and is associated with better response to adjuvant chemotherapy with 5-fluorouracil (5-FU). In this study we have investigated the association between the MSI status and the mRNA expression as well as the polymorphisms of the cellular target of 5-FU therapy, thymidylate synthase. Polymorphisms in the 3'- and the 5'-UTR of the TS gene were determined by a PCR assay in 53 colorectal cancer tissues. TS mRNA was quantified by real-time RT-PCR. Data were correlated with the MSI phenotype. There was neither a significant correlation between the polymorphisms in the TS gene and the MSI phenotype nor between the mRNA expression and MSI status. CRC with a 3R/3R or 2R/3R genotype showed a significantly higher TS mRNA expression than those with 2R/2R genotype (p=0.001 and p=0.026, respectively). No association was seen between the polymorphism of the 3'-UTR and mRNA expression. From our results, we conclude that there is no association between MSI status and TS expression. Samples containing the 3R/3R or 2R/3R genotype of TS seem to have higher mRNA levels perhaps due to a higher mRNA stability. Polymorphic variants of the 3'-UTR do not influence the TS mRNA level. Genotyping of the 5'-UTR and quantitation of TS mRNA levels might serve as predictors for the response to 5-FU based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010882

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Polymorphism in the 3'-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy.

Authors:  Jian-Wei Lu; Chang-Ming Gao; Jian-Zhong Wu; Hai-Xia Cao; Kazuo Tajima; Ji-Feng Feng
Journal:  J Hum Genet       Date:  2006-01-20       Impact factor: 3.172

2.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

3.  Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance.

Authors:  Sanjay Popat; Richard Wort; Richard S Houlston
Journal:  BMC Cancer       Date:  2006-06-05       Impact factor: 4.430

4.  Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.

Authors:  M K H Maus; D L Hanna; C L Stephens; S H Astrow; D Yang; P P Grimminger; F Loupakis; J H Hsiang; G Zeger; T Wakatsuki; A Barzi; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2014-12-23       Impact factor: 3.550

5.  Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.

Authors:  Heidi Schwarzenbach
Journal:  EPMA J       Date:  2010-06-04       Impact factor: 6.543

6.  Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences.

Authors:  Hidekazu Kuramochi; Kazumi Uchida; Jeffery H Peters; Daisuke Shimizu; Daniel Vallbohmer; Sylke Schneider; Kathleen D Danenberg; Peter V Danenberg
Journal:  BMC Cancer       Date:  2009-05-21       Impact factor: 4.430

7.  Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.

Authors:  Søren A Jensen; Ben Vainer; Mogens Kruhøffer; Jens B Sørensen
Journal:  BMC Cancer       Date:  2009-01-20       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.